Brief: AstraZeneca Says Datroway Approved In US For 1L Triple-Negative BC
26/05/2026 07:17
May 26 (Reuters) - AstraZeneca PLC AZN.L: ASTRAZENECA PLC - DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC ASTRAZENECA - FDA APPROVAL OF DATROWAY FOLLOWS PRIORITY REVIEW BASED ON PHASE III DATA Source text: ID:nRSZ6558Fa Further company coverage: AZN.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daiichi Sankyo Co
See all newsNotice Regarding Conclusion Of A Money Loan Agreement With Financial Covenants
Brief: Daiichi Sankyo - Won Approval To Market 'Vanflyta (Quizartinib)' In China For First-Line Treatment Of Flt3-Itd Mutation-Positive Acute Myeloid Leukemia
Brief: Daiichi Sankyo Concludes pCPA Letter Of Intent For Vanflyta®
Brief: AstraZeneca Says Datroway Approved In US For 1L Triple-Negative BC
Brief: EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy